glycine has been researched along with Neutropenia in 5 studies
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ixazomib is approved for use in combination with lenalidomide and dexamethasone (IRd) for patients with multiple myeloma (MM) who received at least one previous therapy." | 8.12 | Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma. ( Chudej, J; Guman, T; Hlebaskova, M; Kucerikova, M; Sokol, J; Stasko, J; Stecova, N; Valekova, L, 2022) |
| " A 66-year-old male treated with combined paclitaxel (PTX) and S-1 suffered from ARDS following neutropenia." | 7.74 | [Good response in ARDS treated with sivelestat sodium hydrate during chemotherapy for cholangiocarcinoma]. ( Hanada, N; Hori, K; Kusano, S; Momi, H, 2007) |
| "Ixazomib is approved for use in combination with lenalidomide and dexamethasone (IRd) for patients with multiple myeloma (MM) who received at least one previous therapy." | 4.12 | Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma. ( Chudej, J; Guman, T; Hlebaskova, M; Kucerikova, M; Sokol, J; Stasko, J; Stecova, N; Valekova, L, 2022) |
| "Sivelestat significantly attenuated LPS-induced ALI during recovery from neutropenia, and this effect was associated with MerTK induction." | 3.85 | Inhibition of neutrophil elastase contributes to attenuation of lipopolysaccharide-induced acute lung injury during neutropenia recovery in mice. ( Kim, IK; Kim, JW; Lee, DG; Lee, HY; Lee, JM; Lee, SH; Rhee, CK; Yeo, CD, 2017) |
| " A 66-year-old male treated with combined paclitaxel (PTX) and S-1 suffered from ARDS following neutropenia." | 3.74 | [Good response in ARDS treated with sivelestat sodium hydrate during chemotherapy for cholangiocarcinoma]. ( Hanada, N; Hori, K; Kusano, S; Momi, H, 2007) |
| "Ixazomib is an investigational proteasome inhibitor that has shown preclinical activity in lymphoma models." | 2.79 | Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma. ( Assouline, SE; Chang, J; Cheson, BD; Di Bacco, A; Gupta, N; Hamburg, S; Hui, AM; Martin, P; Reyes, R; Rifkin, R; Shou, Y; Yu, J, 2014) |
| "Gemcitabine was administered on days 1, 8, and 15 on a 28-day cycle and rigosertib on days 1, 4, 8, 11, 15, and 18." | 2.77 | Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. ( Adjei, AA; Dy, GK; Eckhardt, SG; Jimeno, A; Ma, WW; Maniar, M; Messersmith, WA; Ren, C; Weekes, CD; Whitworth, A; Wilhelm, F, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sokol, J | 1 |
| Guman, T | 1 |
| Chudej, J | 1 |
| Hlebaskova, M | 1 |
| Stecova, N | 1 |
| Valekova, L | 1 |
| Kucerikova, M | 1 |
| Stasko, J | 1 |
| Assouline, SE | 1 |
| Chang, J | 1 |
| Cheson, BD | 1 |
| Rifkin, R | 1 |
| Hamburg, S | 1 |
| Reyes, R | 1 |
| Hui, AM | 1 |
| Yu, J | 1 |
| Gupta, N | 1 |
| Di Bacco, A | 1 |
| Shou, Y | 1 |
| Martin, P | 1 |
| Lee, JM | 1 |
| Yeo, CD | 1 |
| Lee, HY | 1 |
| Rhee, CK | 1 |
| Kim, IK | 1 |
| Lee, DG | 1 |
| Lee, SH | 1 |
| Kim, JW | 1 |
| Ma, WW | 1 |
| Messersmith, WA | 1 |
| Dy, GK | 1 |
| Weekes, CD | 1 |
| Whitworth, A | 1 |
| Ren, C | 1 |
| Maniar, M | 1 |
| Wilhelm, F | 1 |
| Eckhardt, SG | 1 |
| Adjei, AA | 1 |
| Jimeno, A | 1 |
| Hanada, N | 1 |
| Kusano, S | 1 |
| Hori, K | 1 |
| Momi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Characterized With Genomic Abnormalities of Adverse Adverse Prognostic[NCT03683277] | Phase 2 | 26 participants (Actual) | Interventional | 2019-11-03 | Terminated (stopped due to Recruitment issue, 26 patients enrolled instead of 70 initially planned) | ||
| Phase I Dose Escalation Study of Gemcitabine and ON 01910.Na in Patients With Advanced or Metastatic Solid Tumors[NCT01125891] | Phase 1 | 39 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for glycine and Neutropenia
| Article | Year |
|---|---|
Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.
Topics: Adult; Aged; Boron Compounds; Diarrhea; Female; Glycine; Humans; Lymphoma, Follicular; Lymphoma, T-C | 2014 |
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Ce | 2012 |
3 other studies available for glycine and Neutropenia
| Article | Year |
|---|---|
Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cohort Studies | 2022 |
Inhibition of neutrophil elastase contributes to attenuation of lipopolysaccharide-induced acute lung injury during neutropenia recovery in mice.
Topics: Acute Lung Injury; Animals; Bronchoalveolar Lavage Fluid; Female; Glycine; Intercellular Adhesion Mo | 2017 |
[Good response in ARDS treated with sivelestat sodium hydrate during chemotherapy for cholangiocarcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2007 |